CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

Rhea-AI Summary

CathVision (BSX) announced two milestones on Dec 10, 2025: the appointment of Eric Thepaut as independent Chairman of the Board and the commercial release of ECGenius System Version 3.5.

Thepaut joins after retirement from Boston Scientific, bringing commercial and integration experience. CathVision said ECGenius and Cardialytics were FDA-cleared in 2023 and ECGenius received CE mark in 2025. Version 3.5 adds user interface flexibility, DICOM archiving, hospital worklist integration, hardware refinements to reduce post-pacing artifacts, and streamlined 12-lead ECG capture.

Positive

• Appointed Eric Thepaut as independent chairman on Dec 10, 2025
• Commercial release of ECGenius Software Version 3.5 on Dec 10, 2025
• ECGenius and Cardialytics FDA-cleared in 2023
• ECGenius CE-marked in 2025

Negative

• U.S. and European commercial expansion is described as preparatory, not completed

News Market Reaction

+0.18%

1 alert

+0.18% News Effect

On the day this news was published, BSX gained 0.18%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ECGenius software version: Version 3.5 FDA clearance year: 2023 CE-mark year: 2025 +1 more

4 metrics

ECGenius software version Version 3.5 Commercial release of ECGenius System software

FDA clearance year 2023 ECGenius and Cardialytics FDA-cleared in 2023

CE-mark year 2025 ECGenius CE-marked in 2025

Prospective clinical study 1 study Prospective clinical study with PFAnalyzer module mentioned

Market Reality Check

Price: $93.79 Vol: Volume 10,473,403 is 1.07...

normal vol

$93.79 Last Close

Volume Volume 10,473,403 is 1.07x the 20-day average, indicating slightly elevated trading activity before this announcement. normal

Technical Shares at $91.75 were trading below the $101.28 200-day moving average, reflecting a weaker intermediate trend.

Peers on Argus

Peers were mixed: SYK -0.7%, MDT -1.62%, EW -0.13%, ABT +0.21%, PHG -0.07%, sugg...

Peers were mixed: SYK -0.7%, MDT -1.62%, EW -0.13%, ABT +0.21%, PHG -0.07%, suggesting no clear sector-wide move tied to this news.

Historical Context

5 past events · Latest: Nov 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 03	Investor conferences	Neutral	-2.1%	Announced participation in two late-2025 healthcare investor conferences.
Oct 22	Earnings results	Positive	+4.0%	Reported strong Q3 2025 sales growth and EPS above guidance ranges.
Oct 17	Acquisition agreement	Positive	+1.5%	Agreed to acquire Nalu Medical to expand neuromodulation portfolio.
Sep 02	Investor day & call	Neutral	+1.1%	Announced 2025 Investor Day and timing for Q3 2025 earnings call.
Aug 05	Facilities lease	Neutral	-1.8%	Disclosed long-term office lease in Austin creative campus.

Pattern Detected

Fundamental and M&A news for Boston Scientific tended to see positive price alignment, while neutral conference or facilities updates often showed divergent moves.

Recent Company History

Over the last six months, Boston Scientific reported strong Q3 2025 results and an accretive Nalu Medical acquisition, both followed by positive one-day moves. More routine items—conference schedules, investor events, and a facility lease—saw mixed or negative reactions. Against this backdrop, today’s management-focused news about a partner company operating in cardiac electrophysiology fits within a pattern where strategically relevant, but indirect, items do not always drive BSX’s share price.

Market Pulse Summary

This announcement highlights leadership changes and product enhancements at CathVision, a company op...

Analysis

This announcement highlights leadership changes and product enhancements at CathVision, a company operating in cardiac electrophysiology where Boston Scientific also has interests. The appointment of a former BSX regional president and the FDA-cleared and CE-marked ECGenius platform underscore ongoing innovation in arrhythmia care. In context, investors watching BSX typically focus on how such ecosystem developments may influence its electrophysiology portfolio, alongside core metrics like revenue growth and acquisition execution.

Key Terms

cardiac electrophysiology, pulse field ablation, atrial fibrillation, dicom, +3 more

7 terms

cardiac electrophysiology medical

"improving clinical outcomes in cardiac electrophysiology through high-fidelity signal"

The medical specialty that studies and treats the heart’s electrical system — how electrical signals start and travel to make the heart beat and what causes irregular heart rhythms. It matters to investors because tests, procedures and devices from this field (like diagnostic tools, catheters, implants and drugs) drive clinical demand, regulatory reviews and company revenue; think of it as the “wiring and circuit-breakers” sector for the heart that determines market opportunity for related technologies.

pulse field ablation medical

"successful launch of the company's first Pulse Field Ablation (PFA) device"

Pulse field ablation is a medical procedure that uses very short bursts of electrical energy to destroy tiny patches of heart tissue that cause abnormal rhythms, like clearing a few roots without digging up the whole garden. It matters to investors because it represents a potentially faster, more selective and safer alternative to older techniques, influencing device demand, hospital adoption, treatment costs and regulatory and reimbursement outcomes.

atrial fibrillation medical

"improving outcomes for patients suffering from atrial fibrillation."

Atrial fibrillation is a common heart rhythm problem in which the heart’s upper chambers quiver instead of delivering steady, strong pumps, like a washing machine on an unbalanced cycle. It matters to investors because it increases use of medications, medical devices, hospital care and long‑term monitoring, drives demand for new treatments and diagnostics, and can affect healthcare costs, regulatory decisions and revenue prospects across drug, device and insurance markets.

dicom technical

"IT Integration Features: Archiving studies in DICOM format and reading patient"

DICOM is a set of technical rules that lets medical imaging devices and software—like X‑ray, CT, MRI machines and hospital image archives—store, label and share images and related patient information so different systems can understand each other. For investors, DICOM compliance matters because companies that build imaging equipment, software or data services must follow these rules to ensure their products work with hospital systems, which affects market access, sales and regulatory acceptance much like a universal plug adapter enables devices to connect in any country.

12-lead ecg medical

"12-Lead ECG Capture Workflow: Streamlined capture directly to the event log"

A 12-lead ECG (electrocardiogram) is a common medical test that records the heart’s electrical activity from 12 different viewpoints using sensors on the chest and limbs—like taking a multi-angle snapshot of the heart’s rhythm and signals. It matters to investors because it is a routine tool for detecting heart problems and monitoring safety in clinical trials and product use; abnormal findings can influence regulatory decisions, trial outcomes, or a healthcare company's market value.

ce-marked regulatory

"Cardialytics FDA-cleared in 2023, and ECGenius CE-marked in 2025"

CE-marked indicates a product meets European Union requirements for safety, performance and legal compliance, allowing it to be sold across the European Economic Area. For investors, a CE mark is like a passport or safety stamp — it reduces regulatory and market-entry risk, can speed sales and adoption across many countries, and signals the maker completed required testing and documentation, which can affect revenue forecasts and valuation.

fda-cleared regulatory

"With ECGenius and Cardialytics FDA-cleared in 2023"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. Not financial advice.

COPENHAGEN, Denmark, Dec. 10, 2025 /PRNewswire/ -- CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System.

Eric Thepaut Appointed Independent Chairman of the Board

Eric Thepaut joins CathVision following his recent retirement from Boston Scientific Corporation (NYSE: BSX), where he served as President, EMEA. He brings extensive leadership experience in finance, global commercial operations, and organizational development, with a long track record of scaling teams and businesses across multiple geographies. 

He led the integration and growth of many acquisitions as well as launched many new technologies. Most recently, he oversaw the successful launch of the company's first Pulse Field Ablation (PFA) device, advancing treatment options for electrophysiologists and improving outcomes for patients suffering from atrial fibrillation.

"I am pleased to join a very strong team that is delivering a new generation of EP recording technology," said Eric Thepaut, Independent Chairman of the Board. "CathVision's high-signal-quality ECGenius System, combined with its clinical module suite, Cardialytics™, has tremendous potential to help electrophysiologists improve the diagnosis and treatment of cardiac arrhythmias. The recently completed prospective clinical study with PFAnalyzer module gives promise that we will bring electrophysiology back to PFA "

Eric added: "With ECGenius and Cardialytics FDA-cleared in 2023, and ECGenius CE-marked in 2025, CathVision is now preparing its commercial growth in the United States and Europe. This is an exciting moment for the company, and I look forward to supporting the team as CathVision expands its clinical and commercial footprint."

CathVision Releases ECGenius® Software Version 3.5

CathVision also announced the commercial availability of Version 3.5 of the ECGenius® Software. This release introduces hardware and software enhancements designed to improve workflow efficiency and system performance, while maintaining the system's existing intended use.

Selected updates in Version 3.5 include:

• User Interface Flexibility: Options for page reordering, catheter renaming, polarity visualization, and analog output gain adjustment.
• IT Integration Features: Archiving studies in DICOM format and reading patient information from hospital worklists.
• Hardware Refinements: Adjustments to reduce post-pacing artifacts.
• 12-Lead ECG Capture Workflow: Streamlined capture directly to the event log for improved documentation efficiency.

"These updates reflect feedback from physicians and clinical engineers," said Mads Emil Matthiesen. "Version 3.5 strengthens the ECGenius System platform and supports ongoing development of clinical modules."

About CathVision

CathVision develops advanced electrophysiology recording technology and intelligent software designed to improve the diagnosis and treatment of cardiac arrhythmias. Through high-fidelity signal acquisition and AI-driven analytics, CathVision aims to provide physicians with greater clarity, consistency, and confidence during ablation procedures.

Photo: https://mma.prnewswire.com/media/2842487/Eric_Thepaut.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cathvision-announces-appointment-of-eric-thepaut-as-independent-chairman-of-the-board-and-releases-ecgenius-system-version-3-5--302637719.html

SOURCE CathVision

FAQ

Who is Eric Thepaut and what role did he take at CathVision (BSX) on Dec 10, 2025?

Eric Thepaut was named independent Chairman of the Board; he recently retired from Boston Scientific where he served as President, EMEA.

What does the ECGenius System Version 3.5 release mean for CathVision (BSX) customers?

Version 3.5 adds UI flexibility, DICOM archiving, hospital worklist integration, reduced post-pacing artifacts, and streamlined 12-lead ECG capture.

Are ECGenius and Cardialytics cleared for use in the U.S. and Europe for CathVision (BSX)?

According to the announcement, ECGenius and Cardialytics were FDA-cleared in 2023 and ECGenius received CE mark in 2025.

Will CathVision (BSX) immediately expand commercial operations in the United States after these announcements?

The company said it is preparing commercial growth in the United States and Europe, indicating expansion plans but not an immediate completed rollout.

Did CathVision disclose clinical results linked to the PFAnalyzer module in the Dec 10, 2025 announcement?

The announcement noted a recently completed prospective clinical study with the PFAnalyzer module but did not disclose detailed results.